Protandim
 |
|
| Public | |
| Traded as | NASDAQ: LFVN |
| Industry | Multi-level marketing |
| Founded | 2003 |
| Headquarters | Salt Lake City, Utah, United States |
|
Area served
|
United States, Canada, Japan, Mexico, Australia, Hong Kong |
|
Key people
|
Darren Jensen President, CEO Robert M. Urban COO Mark Jaggi CFO Joe M. McCord Chief Science Officer (retired) |
| Products | Dietary supplements, skin care |
| Revenue |
 US$ 208.2 million (2013) |
| US$ 12.1 million | |
| Website | www |
Protandim is a patenteddietary supplement marketed by LifeVantage Corporation (NASDAQ: LFVN; formerly LifeLine Therapeutics, Lifeline Nutraceuticals, and Yaak River Resources, Inc), a Utah-based multi-level marketing company. The manufacturers of Protandim claim the product can indirectly increase antioxidant activity by upregulating endogenous antioxidant factors such as the enzymes superoxide dismutase (SOD) and catalase, as well as the tripeptide glutathione. Like all dietary supplements, Protandim has not been evaluated by the U.S. Food and Drug Administration (FDA) and "is not intended to diagnose, treat, cure, or prevent any disease." No published peer-review studies have ever shown it effective in humans.
In 2003, Lifeline Therapeutics, a privately held Denver-based nutraceutical licensing and marketing company, entered into a agreement with Massachusetts biotechnology company CereMedix for the rights to market CMX-1152, an experimental peptide-based compound, under the brand name "Protandim" (also sometimes referred to at that time as "Rholen," "Rejuven8r" and "ependymin"). CereMedix was a ten percent owner of Lifeline and members of the CereMedix management board served on Lifeline’s board of directors. CMX-1152 was claimed to upregulate the production of the endogenous antioxidant enzymes superoxide dismutase, catalase, and glutathione peroxidase, and to offset the ageing process.
CMX-1152 was due to be marketed as an over the counter anti-aging pill in June 2004 after completing human clinical trials. However, plans to market the CMX-1152 version of Protandim fell through and in April 2004 Lifeline Therapeutics announced that it would instead be marketing a different (non-peptide) dietary supplement under the name “Protandim CF” (to distinguish it from the peptide version initially developed by Cermedix). The new version of Protandim, a combination of 5 common herbal ingredients including turmeric and green tea was invented following “months of extensive research and development” by Lifeline employees Paul Myhill and William Driscoll (a former oil company executive), who together hold the patent on the product, and it was launched in February 2005. Myhill and Driscoll resigned from the company later that year.
...
Wikipedia